Sanofi group of France and GlaxoSmithKline of the United Kingdom issued a press release on the 23rd, saying that the recombinant protein candidate new coronal vaccine jointly developed by the two pharmaceutical companies has achieved "satisfactory" results in the global phase III clinical trial. The experimental data showed that the protective efficacy of two doses of the candidate vaccine against severe and hospitalized cases of new crown was 100%, the protective efficacy against moderate or severe diseases of new crown was 75%, and the protective efficacy against symptomatic infection of new crown was 57.9%. In addition, the candidate vaccine as a booster can effectively improve the level of neutralizing antibody in volunteers. The candidate vaccine was well tolerated in young and elderly adults and no safety problems were observed, the communique said. At present, the two companies are communicating with regulatory agencies such as the U.S. Food and Drug Administration and the European drug administration, and plan to submit all test data related to the vaccine. The two companies launched the global phase III clinical trial at the end of May last year. They originally planned to recruit more than 35000 volunteers over the age of 18, but this bulletin shows that there are only more than 10000 actual participants. According to French media reports, the trial was delayed because it was difficult to find volunteers who had never been infected with COVID-19. In September last year, Pfizer announced that it would give up its research and development of new mRNA vaccines to avoid wasting its resources in the US mRNA market. (Xinhua News Agency)